Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Safety

U.S. pushes for protections by India

by Glenn Hess, special to C&EN
May 9, 2016 | A version of this story appeared in Volume 94, Issue 19

India remains on a “priority watch list” of nations that have inadequate systems for protecting and enforcing U.S. intellectual property (IP) rights, notably those for pharmaceuticals, the Obama Administration says in a congressionally mandated report. The annual list, released recently by the Office of the U.S. Trade Representative, imposes no sanction but aims to pressure governments into strengthening their IP laws and cracking down on piracy and counterfeiting. The report says India “has not taken the opportunity to address long-standing and systemic deficiencies in its IP regime” and cites a litany of concerns. For instance, it points to the “unpredictable application” of India’s patent law, which can be used to deny patent term extensions when drug companies make small modifications to existing medicines. However, consumer advocates argue that efforts by the U.S. to strengthen the pharmaceutical industry’s patent rights could restrict generics competition worldwide. “It’s outrageous that the U.S. government is once again attempting to stand in the way of India and other developing countries’ efforts to increase access to affordable, lifesaving medicines,” says the nonprofit group Doctors Without Borders.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.